12:00 AM
 | 
Mar 06, 2000
 |  BC Week In Review  |  Company News  |  Deals

Cambridge Antibody, Human Genome Sciences deal

HGSI said it will invest $67 million under a 10-year alliance with CAT to develop human antibodies. HGSI will have rights to use CAT's phage display technology to develop an unlimited number of human antibodies for both therapeutic and diagnostic applications...

Read the full 182 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >